In medicine, a delay in diagnosis is quite often fatal for the patientespecially when it comes to cancer or heart disease. To avoid this, we would have to find a faster way to diagnose these pathologies. After working on the subject, scientists from Imperial College London, MIT, and the Max Delbrück Center for Molecular Medicine in Berlin seem to have finally developed a promising innovation in this area. This is part of a study published on August 4, 2022, in the journal Nature Nanotechnologywhich researchers have unveiled a new test dubbed “CrisprZyme“. The latter would favor the diagnosis des cancers and other cardiovascular diseases. According to the scientists behind this study, this famous test must be used at room temperature. Concretely, it would work by quickly detecting certain biomarkers (molecular signals, editor’s note) of the organismwhich are precisely intended to diagnose or monitor the evolution of a disease.
Furthermore, the authors of this study point out that the CrisprZyme test would provide results through a simple colorimetric analysis. This would therefore make it possible to reveal the quantity of biomarkers present in a sample, without having to send said sample to a laboratory. “CrisprZyme is a simpler diagnostic than those currently available. What sets it apart is that it can tell us how much of the biomarker is present, which can help us not only diagnose a disease, but also to follow its evolution over time“, claimed in a communiqué Professor Molly Stevens, who is one of the main authors of the study in question. Thanks to the CrisprZyme test, patients should therefore no longer wait for the return of their blood tests from the laboratorieswhich can sometimes take days, or even weeks in some cases.
<!–
–>
Cancer detection: more research is still needed
“In addition to potentially improving access to diagnostics in developing countries, this technology might bring us closer to personalized diagnoses at home or in the doctor’s office. By simplifying clinical diagnostic testing, we will be able to provide clinicians with the right tools to test in the same office instead of having to reschedule follow-up scans and blood tests.“, specified Doctor Marta Broto, who is one of the co-authors of the study. However, although CrisprZyme test looks promising, scientists believe that further research is still needed. “After further development and laboratory testing, we hope this test can bring us closer to personalized medicine, where treatment is tailored more specifically to patient needs.“, underlined the authors of the study.
